Evidence
How we made the decision
How we made the decision
We check our guidelines regularly to ensure they remain up to date. We based the decision on surveillance 8 years after the publication of atopic eczema in under 12s: diagnosis and management (2007) NICE guideline CG57.
For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual'.
Previous surveillance update decisions for the guideline are on our website.
New evidence
We found 24 new studies in a search for randomised controlled trials and systematic reviews published between 01 October 2013 and 17 November 2015. We also considered 27 additional studies identified by members of the Guideline Committee who originally worked on this guideline. A further study was identified through post-publication communications.
Evidence identified in previous surveillance 4 and 6 years after publication of the guideline was also considered. This included 64 studies.
From all sources, 116 studies were considered to be relevant to the guideline.
We also checked for relevant ongoing research, which will be evaluated again at the next surveillance review of the guideline.
See appendix A: decision matrix for summaries and references for all new evidence considered.
Views of topic experts
We considered the views of topic experts, including those who helped to develop the guideline and other correspondence we have received since the publication of the guideline.
Views of stakeholders
Stakeholders commented on the decision not to update the guideline and place NICE guideline CG57 on the static list. See appendix B for stakeholders' comments and our responses. Eleven stakeholders commented on this. Eight stakeholders agreed with the proposal not to update the guideline and three disagreed giving information about significant published and on-going trials. NICE guidelines make recommendations based on the best available evidence. New evidence and topic expert feedback suggested that there was new evidence related to assessment of atopic eczema severity, epidemiology, management of trigger factors, treatment, education and adherence to therapy but more work needs to be done. In the current surveillance review none of the new evidence considered was thought to have an impact on the current recommendations.
Eight stakeholders commented on the proposal to place NICE guideline CG57 on the static list. Six stakeholders agreed and two disagreed with this proposal. Given the information provided during the consultation process we decided not to place NICE guideline CG57 on the static list.
See ensuring that published guidelines are current and accurate in 'Developing NICE guidelines: the manual' for more details on our consultation processes.
This page was last updated: